Breaking News Instant updates and real-time market news.

BLUE

Bluebird Bio

$88.72

-0.27 (-0.30%)

, NVO

Novo Nordisk

$51.41

-0.09 (-0.17%)

11:18
10/09/19
10/09
11:18
10/09/19
11:18

Bluebird Hem A collaboration not stock moving, but worth monitoring, says Stifel

Stifel analyst Benjamin Burnett said he does not expect news that Blubird Bio (BLUE) is entering the Hemophila A race via a collaboration with Novo Nordisk (NVO) to be stock moving, but he does think it is "certainly worth monitoring." Biomarin's (BMRN) gene therapy candidate Valrox sets "the bar for genetic medicines in heme A today," said Burnett, who noted that gene therapies from Spark (ONCE) and Pfizer (PFE) are also in the clinic. However, "there does appear to be room for efficacy improvement as none of the clinical data generated from genetic medicines to date is a clear home run," Burnett added in his note to investors. He keeps a Hold rating on Bluebird Bio shares.

BLUE

Bluebird Bio

$88.72

-0.27 (-0.30%)

NVO

Novo Nordisk

$51.41

-0.09 (-0.17%)

BMRN

BioMarin

$65.00

0.18 (0.28%)

ONCE

Spark Therapeutics

$97.13

-0.75 (-0.77%)

PFE

Pfizer

$35.59

0.15 (0.42%)

  • 11

    Oct

  • 11

    Oct

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

BLUE Bluebird Bio
$88.72

-0.27 (-0.30%)

08/12/19
08/12/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. NetEase (NTES) downgraded to Neutral from Buy at Goldman Sachs with analyst Bill Liu citing the company's Q2 revenues miss, mainly on soft online games growth. 2. Occidental Petroleum (OXY) downgraded to In Line from Outperform at Evercore ISI with analyst Doug Terreson saying the company's "pledge" for greater capital discipline and enhanced corporate governance "proved fleeting" with the significant decline in return on capital employed due to the Anadarko acquisition. 3. Adesto Technologies (IOTS) downgraded to Market Perform from Outperform at Northland with analyst Gus Richard saying the company has $34M of high interest debt and needs $10M to pay an earnout by year end, but he thinks the company is holding off on an offering until it reports a "strong" third quarter that will be boosted by an airpod win at Apple (AAPL). 4. Bluebird Bio (BLUE) downgraded to Market Perform from Outperform at William Blair with analyst Raju Prasad saying he's taking a conservative view on the company's transition from a development-stage company to a commercial-stage company. 5. Cemex (CX) downgraded to Market Perform from Outperform at BBVA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/12/19
WBLR
08/12/19
DOWNGRADE
WBLR
Market Perform
William Blair downgrades Bluebird Bio, calls Zynteglo launch 'slow mover'
William Blair analyst Raju Prasad downgraded Bluebird Bio to Market Perform from Outperform saying he's taking a conservative view on the company's transition from a development-stage company to a commercial-stage company. Based on the reimbursement model, the analyst believes that the Zynteglo launch is likely to be a "slow mover." Further, Prasad altered his model for bb2121-bb21217 to reflect the increased BCMA competition from both autologous and allogeneic cell therapy approaches that he says are moving faster through the clinic than he initially anticipated.
09/30/19
STFL
09/30/19
INITIATION
Target $109
STFL
Hold
Bluebird Bio initiated with a Hold at Stifel
Stifel analyst Benjamin Burnett initiated Bluebird Bio with a Hold rating and a price target of $109. The analyst is concerned that the launch of the company's lead product Zynteglo will be slow, which places a risk on it meeting consensus expectations. Burnett adds that the the bull case on Bluebird Bio is hard to justify because of the tough competition in multiple myeloma.
08/12/19
WBLR
08/12/19
DOWNGRADE
WBLR
Market Perform
Bluebird Bio downgraded to Market Perform from Outperform at William Blair
William Blair analyst Raju Prasad downgraded Bluebird Bio to Market Perform from Outperform.
NVO Novo Nordisk
$51.41

-0.09 (-0.17%)

08/13/19
ROTH
08/13/19
NO CHANGE
Target $31
ROTH
Buy
Roth confident Amarin's Vascepa will be 'well-received' by FDA panel
Roth Capital analyst Yasmeen Rahimi noted that the FDA's upcoming Advisory Committee reviewing the sNDA for Amarin's (AMRN) Vascepa will include ten voting and one non-voting committee members, including five endocrinologists, three cardiologists, a biostatistician, a pharmacoepidemiologist, a consumer representative and a non-voting nephrologist. Given that the American Diabetes Association has included Vascepa for CV risk reduction in its recommended treatment guidelines, and the panel has a majority of endocrinologists, she believes that "the committee is primed for a positive reception of Vascepa," Rahimi tells investors. Additionally, the AdCom Chairperson, Dr. Kenneth Burman, previously voted in favor of Novo Nordisk's (NVO) insulin degludec and insulin degludec/aspart when chairing a prior AdCom. Rahimi reads this as a strong sign that he is receptive to new therapies and as a positive for Vascepa's review, she said. The analyst keeps a Buy rating on Amarin shares with a price target of $31.
09/17/19
SBSH
09/17/19
UPGRADE
SBSH
Buy
Novo Nordisk upgraded to Buy from Neutral at Citi
Citi analyst Peter Verdult upgraded Novo Nordisk to Buy from Neutral and raised his price target for the shares to DKK 415 from DKK 334. The analyst believes the company's GLP-1 franchise across diabetes, obesity and nonalcoholic steatohepatitis is "burgeoning." His survey of doctors suggests the company's volume penetration in diabetes could reach 25%-35% versus 7% now. Verdult boosted his earnings estimates for Novo through 2024 up to 20% ahead of consensus expectations.
08/30/19
08/30/19
DOWNGRADE

Fly Intel: Top analyst downgrade
Catch up on today's top analyst downgrades with this list compiled by The Fly: 1. Ulta Beauty (ULTA) downgraded to Neutral from Buy at Citi, to Neutral from Overweight at Piper Jaffray and Atlantic Equities, to Neutral from Outperform at Exane BNP Paribas, to Market Perform from Outperform at Wells Fargo, and to Equal Weight from Overweight at Morgan Stanley. 2. Toronto-Dominion (TD) downgraded to Market Perform from Outperform at BMO Capital with analyst Sohrab Movahedi saying he views the company's Q4 results as a "low-quality meet" and believes the stock's total return potential is now in line with other similarly rated banks. 3. Novo Nordisk (NVO) downgraded to Underperform from Hold at Jefferies with analyst Peter Welford saying he believes the shares at current levels are becoming expensive. 4. UBS (UBS) downgraded to Neutral from Outperform at Exane BNP Paribas. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/30/19
JEFF
08/30/19
DOWNGRADE
JEFF
Underperform
Novo Nordisk downgraded to Underperform from Hold at Jefferies
Jefferies analyst Peter Welford downgraded Novo Nordisk to Underperform from Hold while raising his price target for the shares to DKK 300 from DKK 295. The analyst believes the shares at current levels are becoming expensive. Approval of oral semaglutide is imminent in the U.S., but pricing could drive below-average margins, Welford tells investors in a research note.
BMRN BioMarin
$65.00

0.18 (0.28%)

07/08/19
GSCO
07/08/19
NO CHANGE
GSCO
Goldman Sachs looking to a mid-2020 BioMarin valrox approval
Goldman Sachs analyst Salveen Richter notes that BioMarin has announced plans to submit U.S. and EU marketing applications for its gene therapy valrox in adults with severe hemophilia A in Q4 post recent meetings with regulatory authorities. The analyst anticipates a drug launch in mid-2020-plus, noting that valrox addresses a $30B-$90B severe hemophilia A global opportunity. Richter looks to a Q4 R&D day and the gene therapy program for PKU entering the clinic and is positive into vosoritide Phase 3 results in achondroplasia.
09/13/19
PIPR
09/13/19
NO CHANGE
Target $120
PIPR
Overweight
Piper a buyer of BioMarin shares into next important data catalyst
Piper Jaffray analyst Christopher Raymond sees the vosoritide Phase 3 achondroplasia data, expected by early 2020, as the next important catalyst for shares of BioMarin Pharmaceutical. Assuming no surprises, vosoritide offers a "compelling" commercial premise, with "meaningful" upside to current expectations with little in the way of meaningful competition on the horizon, Raymond tells investors in a research note. The analyst is a buyer into the data and keeps an Overweight rating on BioMarin shares with a $120 price target.
07/12/19
JEFF
07/12/19
NO CHANGE
Target $19
JEFF
Buy
Sangamo should be bought at current share levels, says Jefferies
Jefferies analyst Maury Raycroft attributes the recent weakness in shares of Sangamo Therapeutics (SGMO) to negative sentiment related to BioMarin's (BMRN) valrox's durability. The market may be assuming all hemophilia A gene therapies are the same, Raycroft tells investors in a research note. However, he believes Sangamo's SB-525 could be "best-in-class" and keeps a Buy rating on the shares with a $19 price target. The analyst recommends buying the stock at current levels for the company's hemophilia A opportunity and "robust" pipeline.
07/10/19
WEDB
07/10/19
NO CHANGE
Target $128
WEDB
Outperform
BioMarin weakness 'a buying opportunity' ahead of Q4 catalysts, says Wedbush
Wedbush analyst Liana Moussatos notes that BioMarin has presented results from the valoctocogene roxaparvovec Phase 2 and Phase 3 studies. Following meetings with the FDA and EMA, BioMarin guided to submission of an NDA and MAA for Valrox/Severe Hemophilia A in Q4, she notes. The analyst believes that Valrox has a "clear development lead over" its competition, which may increase the commercial opportunity. Moussatos anticipates approval for Valrox/Hemophilia A as highly likely based on robust efficacy and safety data and projects annual sales could reach over $2B in 2023 after her U.S. estimated launch in year-end 2020. She sees current weakness in the stock as a buying opportunity in front of potentially major clinical and regulatory catalysts in Q4. Moussatos reiterates an Outperform rating and $128 price target on the shares.
ONCE Spark Therapeutics
$97.13

-0.75 (-0.77%)

03/07/19
WBLR
03/07/19
DOWNGRADE
WBLR
Market Perform
William Blair downgrades Spark after filing points to competitive bid process
William Blair analyst Raju Prasad downgraded Spark Therapeutics (ONCE) to Market Perform from Outperform following the filing of its Schedule 14D-9 form that included a summary on the background of the merger agreement with Roche (RHHBY). The filing describes a competitive process that resulted in the final price and furthers the likelihood of the deal closing, Prasad tells investors.
03/25/19
LEHM
03/25/19
DOWNGRADE
Target $115
LEHM
Equal Weight
Spark Therapeutics downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Gena Wang downgraded Spark Therapeutics to Equal Weight from Overweight while raising her price target for the shares to $115 from $74. The analyst cites the pending takeover by Roche (RHHBY) for the downgrade.
05/28/19
FBCO
05/28/19
NO CHANGE
Target $133
FBCO
BioMarin data alleviates valrox durability overhang, re-awakens M&A, says Credit Suisse
Credit Suisse raised its price target for BioMarin (BMRN) to $133 from $131, while nudging up valrox Probability of Success to 75% from 65%. The firm thinks the valoctocogene roxaparvovec data largely alleviates the valrox durability overhang and re-awakens an M&A thesis on BioMarin on the value of its gene therapy platform. The company's de-risked Phase 3 valrox program and established mfg infrastructure put the company's gene tx assets in the valuation range up to that established by the AveXis (AVXS) and Spark Therapeutics (ONCE) transactions, Credit Suisse contends.
06/11/19
JANY
06/11/19
NO CHANGE
JANY
Buy
uniQure weakness a buying opportunity, says Janney Montgomery Scott
Janney Montgomery Scott analyst Yun Zhong said he does not see any fundamental reason for today's weakness in shares of uniQure (QURE), attributing the pullback as likely due to profit taking following some recent strong performance. Roche's (RHHBY) deal to buy Spark Therapeutics (ONCE) in February had a positive impact on the overall gene therapy sector and investor speculation has contributed to an over 30% increase in uniQure shares over the past two weeks, noted Zhong, who said his valuation does not include any acquisition assumption or premium. The analyst, who sees uniQure having the first FDA approval for an AAV gene therapy for hemophilia B and the first AAV gene therapy program in the clinic for Huntington's disease, keeps a Buy rating on the stock and would be a buyer amid today's weakness.
PFE Pfizer
$35.59

0.15 (0.42%)

10/08/19
BMOC
10/08/19
NO CHANGE
Target $39
BMOC
Outperform
Akcea Therapeutics price target lowered to $39 from $43 at BMO Capital
BMO Capital analyst Do Kim lowered his price target on Akcea Therapeutics (AKCA) to $39, noting that while the company's announcement of a Pfizer (PFE) licensing deal yesterday provides "immediate value" to its third lipid asset, the disclosure of a management transition increases the risk of potential disruptions in commercial operations. The analyst still keeps his Outperform rating on the stock, citing significant upside optionality from its "underappreciated pipeline assets" with multiple catalysts expected in the next six months that could unlock value for shareholders.
10/07/19
STFL
10/07/19
NO CHANGE
Target $31
STFL
Hold
Pfizer deal a 'solid, unexpected' win for Akcea Therapeutics, says Stifel
Stifel analyst Paul Matteis called Akcea Therapeutics' (AKCA) licensing agreement for AKCEA-ANGPTL3-LRx with Pfizer (PFE) a "solid and unexpected win" for the former in the wake of recent management turnover. Pfizer will pay up to $1.3B in milestones, including $250M in cash upfront, noted Matteis, who does not think investors were ascribing "all that much credit" to this asset. Matteis has a Hold rating on Akcea shares with a $31 price target.
10/07/19
10/07/19
UPGRADE
Target $25

Outperform
Akcea Therapeutics upgraded to Outperform on Pfizer partnership at Wells Fargo
As previously reported, Wells Fargo analyst Jim Birchenough upgraded Akcea Therapeutics (AKCA) to Outperform from Market Perform following the partnership of AKCEA-ANGPTL3-Lrx with Pfizer (PFE) for development in cardiovascular and metabolic disease indications. The analyst views the partnership as validating of the ANGPTL3 opportunity, with terms "highly favorable" to Akcea, significant market opportunity in NAFLD/NASH/CVD and upfront cash supportive of increased investment in TEGSEDI commercialization, preparation for TTR-LICA and externally focused business development. Birchenough also raised his price target on Akcea's shares to $25 from $24.
09/19/19
JPMS
09/19/19
NO CHANGE
Target $37
JPMS
Neutral
Pfizer price target lowered to $37 from $46 at JPMorgan
JPMorgan analyst Chris Schott lowered his price target for Pfizer (PFE) to $37 from $46 and keeps a Neutral rating on the shares. While the Mylan (MYL)/Upjohn transaction creates a smaller, innovation-driven biopharma business and increases the company's near-term growth prospects, Pfizer's multiple is ahead of itself with the remaining company trading near the top end of the major pharma valuation range, Schott tells investors in a research note. He points out that Pfizer is facing "another major patent cycle" post 2025.

TODAY'S FREE FLY STORIES

HSTM

HealthStream

$26.33

0.13 (0.50%)

16:33
10/21/19
10/21
16:33
10/21/19
16:33
Earnings
HealthStream reports Q3 EPS 11c, consensus 6c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

UGI

UGI Corporation

$48.25

0.07 (0.15%)

16:32
10/21/19
10/21
16:32
10/21/19
16:32
Conference/Events
UGI Corporation management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 12

    Nov

BXS

BancorpSouth

$29.66

0.17 (0.58%)

16:32
10/21/19
10/21
16:32
10/21/19
16:32
Earnings
BancorpSouth reports Q3 net operating EPS 69c, consensus 61c »

Net interest margin -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

TD

Toronto-Dominion

$56.80

0.34 (0.60%)

, AMTD

TD Ameritrade

$37.64

0.85 (2.31%)

16:32
10/21/19
10/21
16:32
10/21/19
16:32
Hot Stocks
TD Bank comments on expected impact of TD Ameritrade Q4 earnings »

TD Bank Group (TD)…

TD

Toronto-Dominion

$56.80

0.34 (0.60%)

AMTD

TD Ameritrade

$37.64

0.85 (2.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 27

    Oct

SECO

Seeco Holding

$6.15

0.2 (3.36%)

16:31
10/21/19
10/21
16:31
10/21/19
16:31
Conference/Events
Seeco Holding management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CE

Celanese

$121.37

-0.3 (-0.25%)

16:31
10/21/19
10/21
16:31
10/21/19
16:31
Earnings
Celanese reports Q3 adjusted EPS $2.53, consensus $2.51 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

OBE

Obsidian Energy

$0.70

(0.00%)

16:30
10/21/19
10/21
16:30
10/21/19
16:30
Hot Stocks
Obsidian Energy CFO David Hendry resigns »

Obsidian Energy said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWAV

ShockWave Medical

$33.98

1.68 (5.20%)

16:30
10/21/19
10/21
16:30
10/21/19
16:30
Initiation
ShockWave Medical initiated  »

ShockWave Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

16:30
10/21/19
10/21
16:30
10/21/19
16:30
Options
Preliminary option volume of 16.2M today »

Preliminary option volume…

TCMD

Tactile Systems

$46.66

-0.42 (-0.89%)

16:29
10/21/19
10/21
16:29
10/21/19
16:29
Initiation
Tactile Systems initiated  »

Tactile Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

SAGE

Sage Therapeutics

$140.90

0.9 (0.64%)

16:29
10/21/19
10/21
16:29
10/21/19
16:29
Conference/Events
Sage Therapeutics management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 12

    Nov

NVRO

Nevro

$85.85

0.88 (1.04%)

16:27
10/21/19
10/21
16:27
10/21/19
16:27
Initiation
Nevro initiated  »

Oppenheimer starts Nevro…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

WSFS

WSFS Financial

$44.14

0.02 (0.05%)

16:26
10/21/19
10/21
16:26
10/21/19
16:26
Earnings
WSFS Financial reports Q3 EPS 98c, consensus 87c »

Net interest income in 3Q…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

QTNT

Quotient

$8.13

-0.33 (-3.90%)

16:25
10/21/19
10/21
16:25
10/21/19
16:25
Conference/Events
Quotient management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 04

    Nov

HXL

Hexcel

$74.60

-1.61 (-2.11%)

, BA

Boeing

$331.09

-13 (-3.78%)

16:25
10/21/19
10/21
16:25
10/21/19
16:25
Hot Stocks
Hexcel CEO sees further uncertainty related to Boeing 737 Max return to service »

CEO Nick Stanage states:…

HXL

Hexcel

$74.60

-1.61 (-2.11%)

BA

Boeing

$331.09

-13 (-3.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

XAIR

Beyond Air

$4.32

(0.00%)

16:25
10/21/19
10/21
16:25
10/21/19
16:25
Initiation
Beyond Air initiated  »

Oppenheimer starts Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRTC

iRhythm

$66.11

-3.22 (-4.64%)

16:25
10/21/19
10/21
16:25
10/21/19
16:25
Initiation
iRhythm initiated  »

iRhythm initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXL

Hexcel

$74.60

-1.61 (-2.11%)

16:24
10/21/19
10/21
16:24
10/21/19
16:24
Hot Stocks
Hexcel reports Q3 gross margin 27.6% vs. $26.5% last year »

Reports Q3 operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

VCYT

Veracyte

$26.18

1.52 (6.16%)

16:23
10/21/19
10/21
16:23
10/21/19
16:23
Hot Stocks
Veracyte says Percepta GSC clinical data results 'inconclusive' »

Veracyte announced data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 12

    Dec

CRVS

Corvus Pharmaceuticals

$3.50

-0.11 (-3.05%)

16:23
10/21/19
10/21
16:23
10/21/19
16:23
Conference/Events
Corvus Pharmaceuticals management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

HXL

Hexcel

$74.60

-1.61 (-2.11%)

16:22
10/21/19
10/21
16:22
10/21/19
16:22
Earnings
Hexcel backs FY19 EPS view $3.43-$3.53 , consensus $3.54 »

Backs FY19 free cash flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AHT

Ashford Hospitality

$2.94

0.01 (0.34%)

, BHR

Braemar Hotels & Resorts

$9.37

0.225 (2.46%)

16:22
10/21/19
10/21
16:22
10/21/19
16:22
Hot Stocks
Braemar Hotels & Resorts declares distribution of shares of Ashford »

Braemar Hotels &…

AHT

Ashford Hospitality

$2.94

0.01 (0.34%)

BHR

Braemar Hotels & Resorts

$9.37

0.225 (2.46%)

AINC

Ashford

$22.33

-0.13 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 12

    Nov

VREX

Varex Imaging

$29.17

0.45 (1.57%)

16:22
10/21/19
10/21
16:22
10/21/19
16:22
Initiation
Varex Imaging initiated  »

Oppenheimer starts Varex…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRY

CryoLife

$24.00

0.32 (1.35%)

16:22
10/21/19
10/21
16:22
10/21/19
16:22
Initiation
CryoLife initiated  »

CryoLife initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

SITC

Site Centers

$15.26

0.165 (1.09%)

16:22
10/21/19
10/21
16:22
10/21/19
16:22
Syndicate
Site Centers files to sell 10.5M shares of common stock »

Goldman Sachs and Morgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 11

    Nov

  • 12

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.